• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

葡萄膜黑色素瘤专家意见:来自第58届眼科肿瘤学组会议的见解

Expert Opinions on Uveal Melanoma: Insights from the 58th Ophthalmic Oncology Group Meeting.

作者信息

Stålhammar Gustav, Vishnevskia-Dai Vicktoria, Verdijk Robert M, Moulin Alexandre

机构信息

Department of Clinical Neuroscience, Division of Eye and Vision, Karolinska Institutet, Stockholm, Sweden.

Ocular Oncology Service, St. Erik Eye Hospital, Stockholm, Sweden.

出版信息

Ocul Oncol Pathol. 2024 Dec;10(4):197-205. doi: 10.1159/000541016. Epub 2024 Aug 27.

DOI:10.1159/000541016
PMID:39660247
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11627587/
Abstract

INTRODUCTION

Clear evidence for the best clinical management of uveal melanoma is lacking in some areas. Therefore, reports on expert opinions in the field can be valuable.

METHODS

A questionnaire comprising 10 questions was distributed to potential participants of the 58th Ophthalmic Oncology Group Meeting in Stockholm, Sweden, in June 2024.

RESULTS

Among 34 respondents, 13 (38%) had >20 years of postresidency experience in ophthalmic oncology. The maximum recommended tumor thickness for ruthenium-106 plaque brachytherapy was 5.7 mm (SD 1.1). Twenty-three respondents (68%) indicated that radiological surveillance for metastatic disease should be conducted irrespective of primary tumor characteristics. A majority (74%) would treat a lesion with a 6 mm diameter and 1.5 mm thickness without waiting for evidence of growth if sufficient risk factors were present. Most experts did not currently recommend sampling of circulating tumor DNA or circulating tumor cells. There were no significant differences in responses based on the experience of respondents (≤20 vs. >20 years) or their annual volume of new cases (≤50 vs. >50).

CONCLUSION

This article reports the opinions of 34 experts in ophthalmic oncology on various contemporary topics in uveal melanoma. The responses illustrate both agreements and differences in opinions among experts.

摘要

引言

在葡萄膜黑色素瘤的最佳临床管理方面,某些领域缺乏明确的证据。因此,该领域的专家意见报告可能很有价值。

方法

2024年6月,向瑞典斯德哥尔摩第58届眼科肿瘤学组会议的潜在参与者发放了一份包含10个问题的问卷。

结果

在34名受访者中,13人(38%)在眼科肿瘤学方面有超过20年的住院后经验。钌-106斑块近距离放射治疗的最大推荐肿瘤厚度为5.7毫米(标准差1.1)。23名受访者(68%)表示,无论原发性肿瘤特征如何,都应进行转移性疾病的放射学监测。如果存在足够的风险因素,大多数人(74%)会在不等待生长证据的情况下治疗直径6毫米、厚度1.5毫米的病变。目前大多数专家不建议对循环肿瘤DNA或循环肿瘤细胞进行采样。根据受访者的经验(≤20年与>20年)或他们每年的新病例数量(≤50例与>50例),回答没有显著差异。

结论

本文报告了34位眼科肿瘤学专家对葡萄膜黑色素瘤各种当代主题的意见。这些回答显示了专家之间意见的一致和分歧。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0f0/11627587/f40cbaa76e39/oop-2024-0010-0004-541016_F04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0f0/11627587/9a833c3cfc61/oop-2024-0010-0004-541016_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0f0/11627587/6004baaac155/oop-2024-0010-0004-541016_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0f0/11627587/9d91e9897162/oop-2024-0010-0004-541016_F03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0f0/11627587/f40cbaa76e39/oop-2024-0010-0004-541016_F04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0f0/11627587/9a833c3cfc61/oop-2024-0010-0004-541016_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0f0/11627587/6004baaac155/oop-2024-0010-0004-541016_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0f0/11627587/9d91e9897162/oop-2024-0010-0004-541016_F03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0f0/11627587/f40cbaa76e39/oop-2024-0010-0004-541016_F04.jpg

相似文献

1
Expert Opinions on Uveal Melanoma: Insights from the 58th Ophthalmic Oncology Group Meeting.葡萄膜黑色素瘤专家意见:来自第58届眼科肿瘤学组会议的见解
Ocul Oncol Pathol. 2024 Dec;10(4):197-205. doi: 10.1159/000541016. Epub 2024 Aug 27.
2
Palladium 103 plaque radiotherapy for uveal melanoma. Clinical experience.钯103敷贴放疗治疗葡萄膜黑色素瘤。临床经验。
Ophthalmology. 1994 Feb;101(2):256-63. doi: 10.1016/s0161-6420(94)31338-8.
3
Brachytherapy With 15- Versus 20-mm Ruthenium 106 Plaques Without Verification of Plaque Position Is Associated With Local Tumor Recurrence and Death in Posterior Uveal Melanoma.15 毫米与 20 毫米铱 106 放射性敷贴器治疗眼后葡萄膜黑色素瘤,未行敷贴器位置验证与局部肿瘤复发和死亡相关。
Int J Radiat Oncol Biol Phys. 2023 Dec 1;117(5):1125-1137. doi: 10.1016/j.ijrobp.2023.06.077. Epub 2023 Jul 9.
4
Iodine Plaque Brachytherapy a Customized Conservative Approach to the Management of Medium/Large-sized Uveal Melanoma.碘斑近距离放射治疗:中/大型葡萄膜黑色素瘤的一种定制化保守治疗方法。
In Vivo. 2024 Jul-Aug;38(4):1814-1822. doi: 10.21873/invivo.13633.
5
(106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence.(106)钌斑块近距离放射治疗葡萄膜黑色素瘤:与局部肿瘤复发相关的因素
Brachytherapy. 2014 Nov-Dec;13(6):584-90. doi: 10.1016/j.brachy.2014.04.002. Epub 2014 May 28.
6
Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients.脉络膜黑色素瘤的斑块放射治疗:1106例连续患者的长期视力结果
Arch Ophthalmol. 2000 Sep;118(9):1219-28. doi: 10.1001/archopht.118.9.1219.
7
Brachytherapy of Uveal Melanomas with Ruthenium-106 Plaques.钌-106 敷贴器治疗脉络膜黑色素瘤
Asian Pac J Cancer Prev. 2016 Dec 1;17(12):5281-5285. doi: 10.22034/APJCP.2016.17.12.5281.
8
Efficacy and complications of ruthenium-106 brachytherapy for uveal melanoma: a systematic review and meta-analysis.钌-106近距离放射治疗葡萄膜黑色素瘤的疗效与并发症:一项系统评价和荟萃分析
J Contemp Brachytherapy. 2021 Jun;13(3):358-364. doi: 10.5114/jcb.2021.106191. Epub 2021 May 18.
9
Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy.钌-106近距离放射治疗后葡萄膜黑色素瘤的长期预后
Front Oncol. 2022 Jan 3;11:754108. doi: 10.3389/fonc.2021.754108. eCollection 2021.
10
Monte Carlo investigation of dose distribution of two model Ru/Rh ophthalmic plaques in a realistic human eye model with different uveal melanoma size.在具有不同葡萄膜黑色素瘤大小的真实人眼模型中,对两种模型Ru/Rh眼用敷贴器剂量分布的蒙特卡罗研究。
Appl Radiat Isot. 2025 Mar;217:111636. doi: 10.1016/j.apradiso.2024.111636. Epub 2024 Dec 13.

引用本文的文献

1
Clinical decision-making for uveal melanoma radiotherapy: comparative performance of experienced radiation oncologists and leading generative AI models.葡萄膜黑色素瘤放疗的临床决策:经验丰富的放射肿瘤学家与领先的生成式人工智能模型的比较表现
Front Oncol. 2025 Aug 14;15:1605916. doi: 10.3389/fonc.2025.1605916. eCollection 2025.
2
Twelve reasons delays in uveal melanoma treatment might affect prognosis.葡萄膜黑色素瘤治疗延迟可能影响预后的十二个原因。
Br J Ophthalmol. 2025 Aug 20;109(9):967-969. doi: 10.1136/bjo-2025-327294.
3
Threshold analysis of mortality outcomes in the collaborative ocular melanoma study (COMS).

本文引用的文献

1
Tailoring surveillance imaging in uveal melanoma based on individual metastatic risk.根据个体转移风险定制葡萄膜黑色素瘤的监测成像。
Can J Ophthalmol. 2025 Apr;60(2):e240-e252. doi: 10.1016/j.jcjo.2024.07.014. Epub 2024 Aug 13.
2
15-Gene Expression Profile and as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1).15 基因表达谱与液体活检作为葡萄膜黑色素瘤的整合预后检测:合作眼肿瘤学组研究第 2 号(COOG2.1)的首次报告。
J Clin Oncol. 2024 Oct;42(28):3319-3329. doi: 10.1200/JCO.24.00447. Epub 2024 Jul 25.
3
Deferral of Treatment for Small Choroidal Melanoma and the Risk of Metastasis: An Investigation Using the Liverpool Uveal Melanoma Prognosticator Online (LUMPO).
协作性眼黑色素瘤研究(COMS)中死亡率结果的阈值分析。
Melanoma Manag. 2025 Dec;12(1):2494977. doi: 10.1080/20450885.2025.2494977. Epub 2025 May 5.
小脉络膜黑色素瘤治疗延迟与转移风险:一项使用利物浦葡萄膜黑色素瘤预后在线工具(LUMPO)的调查
Cancers (Basel). 2024 Apr 22;16(8):1607. doi: 10.3390/cancers16081607.
4
Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma.循环肿瘤DNA作为葡萄膜黑色素瘤液体生物标志物的评估
Invest Ophthalmol Vis Sci. 2024 Feb 1;65(2):11. doi: 10.1167/iovs.65.2.11.
5
Delays between Uveal Melanoma Diagnosis and Treatment Increase the Risk of Metastatic Death.葡萄膜黑色素瘤的诊断和治疗延误增加转移死亡的风险。
Ophthalmology. 2024 Sep;131(9):1094-1104. doi: 10.1016/j.ophtha.2023.11.021. Epub 2023 Nov 21.
6
Surveillance for Metastasis in High-Risk Uveal Melanoma Patients: Standard versus Enhanced Protocols.高危葡萄膜黑色素瘤患者转移的监测:标准方案与强化方案对比
Cancers (Basel). 2023 Oct 17;15(20):5025. doi: 10.3390/cancers15205025.
7
Detection of Circulating Tumor Cells in Patients with Small Choroidal Melanocytic Lesions.检测小脉络膜黑色素瘤患者的循环肿瘤细胞。
Ophthalmology. 2023 Dec;130(12):1290-1303. doi: 10.1016/j.ophtha.2023.07.025. Epub 2023 Aug 2.
8
Brachytherapy With 15- Versus 20-mm Ruthenium 106 Plaques Without Verification of Plaque Position Is Associated With Local Tumor Recurrence and Death in Posterior Uveal Melanoma.15 毫米与 20 毫米铱 106 放射性敷贴器治疗眼后葡萄膜黑色素瘤,未行敷贴器位置验证与局部肿瘤复发和死亡相关。
Int J Radiat Oncol Biol Phys. 2023 Dec 1;117(5):1125-1137. doi: 10.1016/j.ijrobp.2023.06.077. Epub 2023 Jul 9.
9
The prognostic implication of latitude in uveal melanoma: a nationwide observational cohort study of all patients born in Sweden between 1947 and 1989.葡萄膜黑色素瘤中纬度的预后意义:一项对1947年至1989年在瑞典出生的所有患者的全国性观察队列研究。
Discov Oncol. 2022 Oct 31;13(1):116. doi: 10.1007/s12672-022-00584-0.
10
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.特普替尼治疗转移性葡萄膜黑色素瘤的总生存获益。
N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485.